Although there was not a statistical difference in the efficacy of GLP1-RA monotherapy or combination therapy in reducing UACR versus insulin glargine, GLP1-RA treatment is a promising alternative to insulin therapy in DKD due to the lower risk of hypoglycemia, the induced weight loss instead of weight gain with insulin therapy, and a possible reduction in cost. Here, GLP1R is linked to diabetic kidney disease.